Skip to content
Screener

Arcus Biosciences RCUS Business Segments — Other segment items

Similar metrics at other companies

Broadridge Financial Solutions logo
BRTotal Reportable Segments — Other segment items
$121.4M+7.5%
Iron Mountain logo
IRMTOTAL REPORTABLE SEGMENTS — Other segment items
$938.34M+13.0%
CNN
CNNETotal Reportable Segments — Other segment items
$17.4M+89.1%
GLW
GLWTotal Reportable Segments — Other segment items
$2.77B+16.4%
RCI Hospitality Holdings logo
RICKReportable Segments Excluding Other — Other segment items
$0-100%
Veradermics logo
MANEReportable Segment — Other segment items
-$2.63M-411%

Other financials

Income statement

See full
Revenue$41.0M-74.4%
Operating income-$96.0M-1,100%
Net income-$91.0M
EPS (diluted)-$0.72

Balance sheet

See full
Cash & equivalents$150.0M-39.5%
Total debt$114.0M+4.6%
Total equity$464.0M-15.5%
Total assets$924.0M-14.0%

Cash flow

See full
Operating cash flow-$119.0M+10.5%
CapEx-
Free cash flow-$119.0M+10.5%

Valuation

See full
Market cap$3.61B+259%
Enterprise value$3.57B+312%
P/S30.8×+27.0×

Profitability

See full
Operating margin-415.4%-756pp
Net margin-393.2%-663pp
FCF margin-406%

Returns & leverage

See full
Return on equity-90.8%+373pp
Debt / equity0.2×0.0×
Current ratio3.8×-0.7×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.

The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001724521-26-000044
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Late-stage development programs (1)5174111129
Early-stage development and preclinical programs (2)21383980
Compensation and personnel costs5861129128
Depreciation and amortization2255
Interest income, net(5)(8)(11)(18)
Other segment items (3)22264047
Partnership reimbursements(17)(33)(36)(71)
Segment net income (loss) and Consolidated net income (loss)$(91)$(219)$(112)

Item 1. Financial Statements

FAQ

What is Arcus Biosciences's business segments — other segment items?
Arcus Biosciences (RCUS) reported business segments — other segment items of $22M in Q2 2026.
How has Arcus Biosciences's business segments — other segment items changed year-over-year?
Arcus Biosciences's business segments — other segment items decreased by 15.4% year-over-year, from $26M to $22M.
What is the long-term trend for Arcus Biosciences's business segments — other segment items?
Over 3 years (2022 to 2025), Arcus Biosciences's business segments — other segment items has grown at a 0.7% compound annual growth rate (CAGR), from $89M to $91M.
What does business segments — other segment items mean?
Captures miscellaneous operating expenses or income items that are not classified under primary development or personnel categories. This metric is used to track overhead and ancillary costs necessary to support the segment's broader business functions.

Ask your AI about Arcus Biosciences's business segments — other segment items.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude